- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1260251-31-7] Birinapant
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16591 |
| Brand: | MCE |
| CAS: | 1260251-31-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 806.94 |
| Molecular Formula | C42H56F2N8O6 |
| SMILES | FC1=CC2=C(C=C1)C(C[C@H]3N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C3)=C(C(N4)=C(C[C@H]5N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C5)C6=C4C=C(F)C=C6)N2 |
18 Publications Citing Use of MCE
- [1]Cell. 2019 Jul 25;178(3):585-599.e15.
- [2]Cell Death Differ. 2021 Oct;28(10):2888-2899.
- [3]Dev Cell. 2019 Oct 21;51(2):277-291.e4.
- [4]Oncogene. 2022 Jun 9.
- [5]Cell Death Dis. 2021 Jun 23;12(7):641.
- [6]Cell Death Dis. 2020 Feb 5;11(2):94.
- [7]Cancers (Basel). 2022 Mar 19;14(6):1575.
- [8]Cell Oncol (Dordr). 2019 Jun;42(3):319-329.
- [9]J Cell Mol Med. 2021 May 3;25(13):6125-6136.
- [10]Front Microbiol. 2018 Sep 19;9:2022.
- [11]Mol Ther Oncolytics. 2022 Nov 15;27:288-304.
- [12]Mol Ther Oncolytics. 2022.
- [13]Aquaculture. 2021, 736595.
- [14]Mol Med Rep. 2020 Mar;21(3):1251-1257.
- [15]University of Portland. Department of Biology
- [16]Patent. US20210269505A1.
- [17]bioRxiv. 2019 Nov.
- [18]University Regensburg. 2017 Jul.
Summary
Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with K d s of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
IC50 & Target
Kd: 45 nM (XIAP), <1 nM (cIAP1) [1]
In Vitro
Birinapant (TL32711) (30-10000 nM; 24 hours) significantly decreases the viability of SUM190 cells in a dose-dependent manner
[1]
.
Birinapant (TL32711) (30-1000 nM; 4 hours) shows a significant decrease in cIAP1 levels and enhanced PARP cleavage, and induces apoptosis
[1]
.
Birinapant (TL32711) binds with high affinity to the isolated BIR3 domains of cIAP1, cIAP2, and XIAP and the single BIR domain of ML-IAP and rapidly degrades TRAF2-bound cIAP1 and cIAP2 thereby inhibiting TNF-mediated NF-κB activation
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | TRAIL-resistant SUM190 IBC cells |
| Concentration: | 30, 100, 300, 1000, 10000 nM |
| Incubation Time: | 24 hours |
| Result: | Significantly decreased the viability of SUM190 cells in a dose-dependent manner. |
Western Blot Analysis [1]
| Cell Line: | SUM190 cells |
| Concentration: | 30, 300, 1000 nM |
| Incubation Time: | 4 hours |
| Result: | Showed a significant decrease in cIAP1 levels and enhanced PARP cleavage. |
In Vivo
Birinapant (TL32711) (30 mg/kg; i.p.; every third day (*5)) shows antitumor efficacy and are devoid of overt toxicity in preclinical models [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female athymic nude mice (low-passage, patient-derived xenotransplant models of ovarian cancer, colorectal cancer, and melanoma) [2] |
| Dosage: | 30 mg/kg |
| Administration: | Intraperitoneal injection; every third day (*5) |
| Result: | Resulted in inhibition of tumor growth. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02756130 | Jonsson Comprehensive Cancer Center|Alpha Stem Cell Clinic (ASCC)|California Institute for Regenerative Medicine (CIRM)|TetraLogic Pharmaceuticals |
High Grade Fallopian Tube Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
August 1, 2018 | Phase 1|Phase 2 |
| NCT04553692 | IGM Biosciences, Inc. |
Solid Tumor|Colorectal Cancer|Non Hodgkin Lymphoma|Sarcoma|Chondrosarcoma|Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia|Acute Myeloid Leukemia
|
September 23, 2020 | Phase 1 |
| NCT02288208 | TetraLogic Pharmaceuticals |
Hepatitis B
|
November 2014 | Phase 1 |
| NCT01188499 | TetraLogic Pharmaceuticals |
Cancer
|
October 2010 | Phase 1|Phase 2 |
| NCT03803774 | National Cancer Institute (NCI) |
Locally Recurrent Head and Neck Squamous Cell Carcinoma|Nasopharyngeal Squamous Cell Carcinoma|Sinonasal Squamous Cell Carcinoma
|
January 7, 2019 | Phase 1 |
| NCT01940172 | TetraLogic Pharmaceuticals |
Relapsed Epithelial Ovarian Cancer|Relapsed Primary Peritoneal Cancer|Relapsed Fallopian Tube Cancer
|
November 2013 | Phase 1 |
| NCT00993239 | TetraLogic Pharmaceuticals |
Cancer
|
November 2009 | Phase 1 |
| NCT01486784 | Abramson Cancer Center of the University of Pennsylvania |
Acute Myelogenous Leukemia
|
November 2011 | Phase 1|Phase 2 |
| NCT02147873 | TetraLogic Pharmaceuticals |
Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML)
|
June 2014 | Phase 2 |
| NCT01828346 | TetraLogic Pharmaceuticals |
Myelodysplastic Syndrome
|
June 2013 | Phase 1|Phase 2 |
| NCT01573780 | Roswell Park Cancer Institute|TetraLogic Pharmaceuticals |
Unspecified Adult Solid Tumor, Protocol Specific
|
April 2012 | Phase 1 |
| NCT01681368 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Epithelial Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms
|
August 15, 2012 | Phase 2 |
| NCT02587962 | Medivir|Merck Sharp & Dohme LLC |
Solid Tumors
|
August 4, 2017 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 154.91 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2392 mL | 6.1962 mL | 12.3925 mL |
| 5 mM | 0.2478 mL | 1.2392 mL | 2.4785 mL |
| 10 mM | 0.1239 mL | 0.6196 mL | 1.2392 mL |
References
- [1] Allensworth JL, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat. 2013 Jan;137(2):359-71.
- [2] Krepler C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013 Apr 1;19(7):1784-94.
- [3] Nguyen QD, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013 Jul 15;19(14):3914-24.
- [4] Benetatos CA, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.